AR076913A1 - Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucion - Google Patents
Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucionInfo
- Publication number
- AR076913A1 AR076913A1 ARP100101742A ARP100101742A AR076913A1 AR 076913 A1 AR076913 A1 AR 076913A1 AR P100101742 A ARP100101742 A AR P100101742A AR P100101742 A ARP100101742 A AR P100101742A AR 076913 A1 AR076913 A1 AR 076913A1
- Authority
- AR
- Argentina
- Prior art keywords
- solution according
- pharmaceutical solution
- telmisartan
- angiotensin
- cresol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Solucion farmacéutica con un valor del pH de 10 o superior que contiene un antagonista del receptor de angiotensina II, caracterizada porque están contenidos uno o más azucar-alcoholes hasta una concentracion total de 40% a 70% (de preferencia 60-70%), presentando el o los azucar-alcoholes, antes de su adicion a la solucion, un contenido máximo de 1000 ppm en azucar reductor. Reivindicacion 3: La solucion farmacéutica segun la reivindicacion 1 o 2, caracterizada porque en el caso del antagonista del receptor de angiotensina II se trata de Telmisartan. Reivindicacion 6: La solucion farmacéutica segun una de las reivindicaciones 1 a 5, caracterizada porque el valor del pH se alcanza mediante la presencia de meglumina, hidroxido de sodio, hidroxido de potasio o un aminoácido de carácter básico tal como arginina o glutamina. Reivindicacion 7: La solucion farmacéutica segun una de las reivindicaciones 1 a 6, caracterizada porque el antagonista del receptor de angiotensina II, preferiblemente Telmisartan, está presente en una concentracion de 1 a 10 mg/mI, de preferencia 1-5 mg/ml. Reivindicacion 9: La solucion farmacéutica segun una de las reivindicaciones 1 a 8, caracterizada porque el o los azucar-alcoholes se seleccionan del grupo xilitol, maltitol, sorbitol, manitol, eritrita e isomalt. Reivindicacion 11: La solucion farmacéutica segun una de las reivindicaciones 1 a 10, caracterizada porque están anadidos, eventualmente, o-cresol, m-cresol, p-cresol o cloruro de benzalconio como agentes conservantes, solos o en combinacion. Reivindicacion 12: La solucion farmacéutica segun una de las reivindicaciones 1 a 11, caracterizada porque está exenta de antioxidantes o estabilizadores. Reivindicacion 13: La solucion farmacéutica segun una de las reivindicaciones 1 a 12, caracterizada porque es para el tratamiento de la hipertension o de lesiones renales en el hombre, en particular ninos, hombres de edad o personas con dificultades de deglucion; o en animales, en particular perros o gatos. Reivindicacion 20: Recipiente de vidrio o de plástico con o sin coadyuvantes de la dosificacion, caracterizado porque contiene la solucion bebible segun una de las reivindicaciones 1 a 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160771 | 2009-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076913A1 true AR076913A1 (es) | 2011-07-20 |
Family
ID=42340411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101742A Pending AR076913A1 (es) | 2009-05-20 | 2010-05-19 | Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucion |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8871795B2 (es) |
| EP (1) | EP2432452B1 (es) |
| JP (1) | JP5612674B2 (es) |
| KR (1) | KR20120015325A (es) |
| CN (1) | CN102458363A (es) |
| AR (1) | AR076913A1 (es) |
| AU (1) | AU2010251194B2 (es) |
| BR (1) | BRPI1013037A2 (es) |
| CA (1) | CA2761576C (es) |
| CL (1) | CL2011002926A1 (es) |
| CO (1) | CO6470844A2 (es) |
| DK (1) | DK2432452T3 (es) |
| ES (1) | ES2598490T3 (es) |
| MX (1) | MX346039B (es) |
| NZ (1) | NZ597049A (es) |
| PL (1) | PL2432452T3 (es) |
| SG (1) | SG176585A1 (es) |
| TW (1) | TW201109040A (es) |
| WO (1) | WO2010133638A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| US8871795B2 (en) | 2009-05-20 | 2014-10-28 | Boehringer Ingleheim Vetmedica Gmbh | Pharmaceutical oral telmisartan solution |
| JP6377426B2 (ja) * | 2013-06-21 | 2018-08-22 | わかもと製薬株式会社 | 水性医薬組成物 |
| JP6344678B2 (ja) * | 2013-09-27 | 2018-06-20 | キョーリンリメディオ株式会社 | テルミサルタン含有製剤及びその製造方法 |
| CA3067918A1 (en) * | 2017-07-07 | 2019-01-10 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats |
| WO2023158787A1 (en) * | 2022-02-17 | 2023-08-24 | Woolsey Pharmaceuticals, Inc. | Taste-masking oral formulations of fasudil |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1023027B (de) | 1953-07-10 | 1958-01-23 | Hoffmann La Roche | Verfahren zur Herstellung von Polyendialdehyden |
| US4448778A (en) * | 1981-08-03 | 1984-05-15 | Ici Americas Inc. | Maltitol containing gel base systems |
| US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| US6028091A (en) | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| US5614519A (en) * | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
| JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
| EP0820302A1 (en) | 1995-04-07 | 1998-01-28 | Novartis AG | Combination compositions containing benazepril or benazeprilat and valsartan |
| CA2257946A1 (en) | 1996-06-24 | 1997-12-31 | Merck & Co., Inc. | A composition of enalapril and losartan |
| JPH11315034A (ja) | 1998-03-04 | 1999-11-16 | Takeda Chem Ind Ltd | アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途 |
| AU2745199A (en) | 1998-03-04 | 1999-09-20 | Takeda Chemical Industries Ltd. | Sustained-release preparation for aii antagonist, production and use thereof |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| DE19901921C2 (de) | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
| US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| US6737432B2 (en) | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
| DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US20050272649A1 (en) | 2002-08-28 | 2005-12-08 | Hruska Keith A | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
| DE10244681A1 (de) | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| WO2005070463A2 (en) | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| DE102004008804A1 (de) | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mehrschichttablette |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| WO2005123070A1 (en) | 2004-06-09 | 2005-12-29 | Fibrogen, Inc. | Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy |
| CN100364532C (zh) | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| DK1814527T4 (da) * | 2004-11-05 | 2020-12-07 | Boehringer Ingelheim Int | Dobbeltlagstablet omfattende telmisartan og amlodipin |
| US20070026026A1 (en) * | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| EP1970053A1 (en) | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| US8871795B2 (en) * | 2009-05-20 | 2014-10-28 | Boehringer Ingleheim Vetmedica Gmbh | Pharmaceutical oral telmisartan solution |
-
2010
- 2010-05-19 US US13/321,216 patent/US8871795B2/en active Active
- 2010-05-19 WO PCT/EP2010/056895 patent/WO2010133638A1/de active Application Filing
- 2010-05-19 BR BRPI1013037A patent/BRPI1013037A2/pt not_active IP Right Cessation
- 2010-05-19 ES ES10723040.1T patent/ES2598490T3/es active Active
- 2010-05-19 AU AU2010251194A patent/AU2010251194B2/en active Active
- 2010-05-19 PL PL10723040T patent/PL2432452T3/pl unknown
- 2010-05-19 KR KR1020117027620A patent/KR20120015325A/ko not_active Application Discontinuation
- 2010-05-19 JP JP2012511281A patent/JP5612674B2/ja active Active
- 2010-05-19 EP EP10723040.1A patent/EP2432452B1/de active Active
- 2010-05-19 CA CA2761576A patent/CA2761576C/en not_active Expired - Fee Related
- 2010-05-19 AR ARP100101742A patent/AR076913A1/es active Pending
- 2010-05-19 MX MX2011012114A patent/MX346039B/es active IP Right Grant
- 2010-05-19 CN CN2010800319074A patent/CN102458363A/zh active Pending
- 2010-05-19 NZ NZ597049A patent/NZ597049A/en not_active IP Right Cessation
- 2010-05-19 DK DK10723040.1T patent/DK2432452T3/en active
- 2010-05-19 TW TW099115966A patent/TW201109040A/zh unknown
- 2010-05-19 SG SG2011085883A patent/SG176585A1/en unknown
-
2011
- 2011-11-18 CL CL2011002926A patent/CL2011002926A1/es unknown
- 2011-11-30 CO CO11165084A patent/CO6470844A2/es not_active Application Discontinuation
-
2014
- 2014-08-27 US US14/469,750 patent/US10314782B2/en active Active
-
2019
- 2019-04-25 US US16/394,610 patent/US10537523B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10537523B2 (en) | 2020-01-21 |
| MX2011012114A (es) | 2011-12-16 |
| US20120095069A1 (en) | 2012-04-19 |
| JP2012526856A (ja) | 2012-11-01 |
| US20190247305A1 (en) | 2019-08-15 |
| US20140364473A1 (en) | 2014-12-11 |
| PL2432452T3 (pl) | 2017-07-31 |
| BRPI1013037A2 (pt) | 2019-09-24 |
| NZ597049A (en) | 2014-01-31 |
| AU2010251194A1 (en) | 2012-01-19 |
| CL2011002926A1 (es) | 2012-06-22 |
| CA2761576C (en) | 2017-08-22 |
| CO6470844A2 (es) | 2012-06-29 |
| JP5612674B2 (ja) | 2014-10-22 |
| CA2761576A1 (en) | 2010-11-25 |
| TW201109040A (en) | 2011-03-16 |
| EP2432452B1 (de) | 2016-07-27 |
| US10314782B2 (en) | 2019-06-11 |
| EP2432452A1 (de) | 2012-03-28 |
| DK2432452T3 (en) | 2016-10-10 |
| US8871795B2 (en) | 2014-10-28 |
| SG176585A1 (en) | 2012-01-30 |
| ES2598490T3 (es) | 2017-01-27 |
| MX346039B (es) | 2017-03-03 |
| KR20120015325A (ko) | 2012-02-21 |
| CN102458363A (zh) | 2012-05-16 |
| WO2010133638A1 (de) | 2010-11-25 |
| AU2010251194B2 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076913A1 (es) | Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucion | |
| EA201100896A1 (ru) | Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение | |
| PE20080994A1 (es) | Jarabes antihistaminicos, estables al almacenamiento sin azucar | |
| AR054154A1 (es) | Mezcla acida para bebida deportiva destinada a reducir o eliminar el regusto | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| EA201170543A1 (ru) | Жидкий фармацевтический состав, содержащий парацетамол | |
| EA201300053A1 (ru) | Фосфатсвязывающий препарат для удобного приема | |
| RU2016147362A (ru) | Препараты жидкого концетрата циклофосфамида | |
| UA91867C2 (ru) | Применение жидкой композиции на основе гуанидинуксусной кислоты и готовый питьевой продукт, содержащий ее | |
| ES2605495T3 (es) | Solución de atomoxetina | |
| AR076864A1 (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos | |
| ES2388095A8 (es) | Mejoras en y relativas a composiciones farmacéuticas. | |
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| Gautam et al. | Antidepressant-like activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5-HT3 receptor antagonist in behaviour based rodent models: Evidence for the involvement of serotonergic system | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| EA201390950A1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой | |
| CN102772363A (zh) | 一种含泊那珠利的溶液剂及其制备方法 | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| IN2012DN00977A (es) | ||
| ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
| EA201270411A1 (ru) | Синтетический гибрид гидротальцит-эудрагида урсодеоксихолевой кислоты, содержащая его фармацевтическая композиция и способ их получения | |
| ES2422281T3 (es) | Granulado para la formulación de comprimidos bucodispersables | |
| MD3952C2 (ro) | Remediu imunostimulator şi metodă de imunostimulare la porcine (variante) | |
| EA201500367A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения цереброваскулярной патологии и нейродегенеративных заболеваний центральной нервной системы | |
| AR077846A1 (es) | Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |